PLK1

PLK1

A gene on chromosome 16p12.2 that encodes a member of the CDC5/Polo subfamily of serine/threonine protein kinases, which performs several key functions during the M phase of the cell cycle—e.g., regulating centrosome maturation and spindle assembly, removing cohesins from chromosome arms, inactivating anaphase-promoting complex/cyclosome (APC/C) inhibitors, and regulating mitotic exit and cytokinesis.
 
Molecular pathology
Defects in PLK1 are associated with gastric, thyroid and B-cell malignancies, with increased expression linked to a worse prognosis.
Mentioned in ?
References in periodicals archive ?
PCM-075 only targets PLK1 isoform (not PLK2 or PLK3), is oral, and has a 24-hour drug half-life with reversible on-target hematologic toxicities.
PLK1, a kinase, has been shown to be phosphorylated in response to TLR activation and results from RNA interference suggested that PLK1 signaling was involved in the TLR-induced inflammatory response (Hu et al.
PLK1 is over-expressed in several different tumour types, such as breast, prostate, ovarian, lung, gastric and colon cancers, in addition to haematological malignancies.
Expression of PLK1 and survivin in diffuse large B-cell lymphoma.
Tekmira has access to eight InterfeRx licenses at pre-negotiated financial terms, and has identified the first six targets, including ApoB, PLK1, Ebola, WEE1, CSN5 and ALDH2.
Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines.
Bacterial 16S rRNA genes were amplified using the previously published bacterial forward primer PLK1 (Klaschik et al.
Trovagene believes that targeting only PLK1 with reversible on-target activity and an improved dose/scheduling protocol can significantly improve on the long-term outcome observed in previous studies with a PLK inhibitor in AML.
PLK1 is over-expressed in several different tumour types, including breast, prostate, ovarian, lung, gastric and colon cancers, as well as hematological malignancies.
Also, Tekmira will file an 1ND and initiate a Phase I trial for its second product candidate, PLK1 SNALP, in 1H10.
Polo-like kinase-1 (PLK1) was identified as the principal protein kinase that carried out B23 phosphorylation at this site, and these findings point to PLK1 as a very promising cancer drug target.